Sanofi Retained Earnings (Accumulated Deficit) 2010-2024 | SNY
Sanofi retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Sanofi retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
- Sanofi retained earnings (accumulated deficit) for 2023 were $73.054B, a 3.9% increase from 2022.
- Sanofi retained earnings (accumulated deficit) for 2022 were $70.311B, a 5.69% decline from 2021.
- Sanofi retained earnings (accumulated deficit) for 2021 were $74.551B, a 8.69% increase from 2020.
Sanofi Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
2023 |
$73,054 |
2022 |
$70,311 |
2021 |
$74,551 |
2020 |
$68,591 |
2019 |
$57,994 |
2018 |
$ |
2017 |
$ |
2016 |
$ |
2015 |
$ |
2014 |
$ |
2013 |
$ |
2012 |
$ |
2011 |
$ |
2010 |
$ |
2009 |
$ |
Sanofi Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
2024-09-30 |
|
2024-06-30 |
$70,099 |
2024-03-31 |
|
2023-12-31 |
$73,054 |
2023-09-30 |
|
2023-06-30 |
$71,633 |
2023-03-31 |
|
2022-12-31 |
$70,311 |
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-09-30 |
|
2021-03-31 |
|
2020-09-30 |
|
2020-03-31 |
|
2019-09-30 |
|
2019-03-31 |
|
2018-03-31 |
|
2017-12-31 |
|
2017-09-30 |
|
2017-06-30 |
|
2017-03-31 |
|
2016-12-31 |
|
2016-09-30 |
|
2016-06-30 |
|
2016-03-31 |
|
2015-09-30 |
|
2015-06-30 |
|
2014-06-30 |
|
2013-06-30 |
|
2012-06-30 |
|
2012-03-31 |
|
2011-12-31 |
|
2011-09-30 |
|
2011-06-30 |
|
2011-03-31 |
|
2010-12-31 |
|
2010-09-30 |
|
2010-06-30 |
|
2010-03-31 |
|
2009-12-31 |
|
2009-09-30 |
|
2009-06-30 |
|
2009-03-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$128.465B |
$46.611B |
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|